SHERLOCK: This phase II study is testing the effectiveness of a new treatment combination (sotorasib, carboplatin-pemetrexed, and bevacizumab-biosimilar) for people with non-small cell lung cancer whose cancer has a specific type of gene mutation called KRAS G12CPhase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation

Summary

Eligible participants will all receive treatment with targeted therapy (sotorsib and bevacizumab-biosimilar) and combination chemotherapy (carboplatin-pemetrexed). Treatment will be given in two stages: Induction and Maintenance. The Induction stage consists of 4 x 3 weekly cycles of sotorasib (960mg, oral tablets daily) plus pemetrexed (500mg/m2 on Day 1 every 3 weeks via intravenous infusion) plus carboplatin (total dose not exceeding 750mg and calculated for each participant using the Calvert method, on Day 1 every 3 weeks via intravenous infusion) plus bevacizumab-biosimilar (15mg/kg, Day 1 every 3 weeks via intravenous infusion). In the Maintenance stage, participants will receive sotorasib (960mg, oral tablets daily) plus Pemetrexed (500mg/m2 on Day 1 every 3 weeks via intravenous infusion ) plus bevacisumab-biosimilar (15mg/kg, Day 1 every 3 weeks via intravenous infusion).